Med Spa Weight Loss Advertising Rules: FTC and FDA (2026)

A med spa’s weight-loss advertising must be truthful, nonmisleading, and supported by competent and reliable scientific evidence before publication. FDA rules add separate limits for prescription-drug and compounded-product claims: a compounded medication cannot be called FDA-approved, generic, the same as, or clinically equivalent to an FDA-approved product. State law also controls who may own, operate, advertise, and provide the medical service.

What rules govern med spa weight loss advertising?

The FTC evaluates the advertisement’s overall net impression, not just the wording in a disclaimer. Headlines, imagery, before-and-after photos, testimonials, product names, clinician imagery, and landing-page design can create express or implied health claims. If the ad communicates an objective weight-loss, safety, or effectiveness claim, the advertiser generally needs competent and reliable scientific evidence before the campaign runs.

The FDA’s concerns are narrower but highly relevant when an ad names a prescription medication. Promotion cannot misbrand or mislead consumers about FDA approval, safety, effectiveness, quality, source, or equivalence. FDA-approved status belongs to the specific approved product and indication; it does not transfer to a compounded medication or to a med spa’s program.

A useful operating assumption is that the spa owns the consumer-facing brand and marketing process, the medical practice and licensed clinicians own clinical evaluation and prescribing decisions, and the technology partner supports workflow, records, communications, and operational infrastructure. MDLaunchr, through WhiteLabelClinic.com, is one white-label telehealth infrastructure option; it does not replace the spa’s state-law review, clinical entity, prescriber responsibilities, or campaign substantiation.

Which weight-loss claims are allowed or high risk?

The safest advertising describes the service accurately without promising a result, universal eligibility, or a particular medication outcome. Every claim still needs review in context.

This table is a screening tool, not a claim approval. A disclaimer cannot cure a fundamentally deceptive headline or image.

Which weight-loss claims does the FTC flag?

The FTC is particularly concerned with rapid, effortless, permanent, or universal weight-loss messages. Its weight-loss guidance identifies claims such as losing two or more pounds per week for a month without diet or exercise, losing substantial weight regardless of what a consumer eats, keeping weight off permanently after stopping a product, and substantial loss without changing eating or exercise habits as highly problematic without appropriate support.

Visuals can communicate the same claims as words. A dramatic before-and-after image, a dress-size reduction, an inches-lost graphic, or a body-composition illustration may imply a specific outcome even when the caption is vague. The question is what a reasonable consumer takes away from the ad as a whole.

For a med spa, the claim file should be assembled before publication. Keep:

• the exact headline, image, testimonial, call to action, and landing-page copy;
• the study or other evidence supporting each objective claim;
• the studied population, product or program, treatment conditions, and limitations;
• the person who approved the campaign and the approval date; and
• each published version, including social posts, vendor-created ads, and revised pages.

Popular articles, personal anecdotes, and testimonials do not substitute for scientific support. Evidence about an FDA-approved product may not substantiate a different compounded product or a materially different program.

Can a med spa use testimonials and before-and-after photos?

A med spa can use a testimonial only if it reflects the endorser’s honest experience and the advertiser has evidence that the stated result occurred. The testimonial also cannot communicate a result the spa could not claim directly. If the featured outcome is not typical, the ad should clearly and conspicuously communicate the generally expected result, supported by evidence; “results not typical” or “individual results may vary” alone is generally inadequate.

The same responsibility can extend to medical directors, nurses, influencers, affiliates, patient ambassadors, independent contractors, and marketing vendors. Material connections should be disclosed clearly and conspicuously. A vendor’s post is not outside the spa’s risk simply because a contractor wrote it.

Before approving a testimonial, ask:

1. 1What exact result does the words and image communicate?
2. 2Can the spa substantiate that result for the actual product or program?
3. 3Is the experience honestly represented and is any material connection disclosed?
4. 4What result should a consumer generally expect, and is that message supported?
5. 5Does the page distinguish an individual experience from a clinical claim?

What can a med spa say about FDA-approved GLP-1 medications?

A med spa may describe an FDA-approved medication only accurately and in a way consistent with the relevant labeling. For example, the FDA-approved Wegovy label identifies use with a reduced-calorie diet and increased physical activity for chronic weight reduction in specified adults and pediatric patients with obesity and adults with overweight plus a weight-related comorbidity. The label also contains a boxed warning concerning thyroid C-cell tumors and other warnings and limitations.

That does not authorize an advertisement suggesting that the medication is appropriate for every person seeking weight loss, guarantees an outcome, or eliminates the need for individualized clinical evaluation. The FDA’s February 5, 2026 untitled letter concerning a Wegovy advertisement illustrates that even promotion of an FDA-approved product remains subject to claim-specific review. A product can be FDA-approved while a particular headline is inaccurate or misleading.

The ad should separate four things:

• the medical evaluation;
• the weight-management service;
• the FDA-approved medication, if offered; and
• the dispensing pharmacy or compounder.

The spa should not present itself as the prescriber or pharmacy unless that description is legally and factually accurate. Clinical decisions remain with independently licensed clinicians acting within their authority.

Can a med spa advertise compounded semaglutide or tirzepatide?

A med spa can describe a compounded medication only accurately and without implying FDA approval, FDA review, or equivalence to an approved product. FDA guidance warns against calling a compounded product a generic version of, the same as, identical to, or clinically proven to produce the same results as an FDA-approved drug. FDA also warns against suggesting that a pharmacy or outsourcing facility is “FDA-approved” or “FDA-licensed” in that sense.

A review may consider wording such as: “A clinician may determine whether an FDA-approved medication or, when legally appropriate, a compounded medication is suitable for you. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.” The statement does not replace state-required disclosures, product-specific review, or legal review.

Do not use approved-product branding, imagery, or names in a way that makes a compounded medication appear to be the approved product. Do not describe compounded semaglutide or tirzepatide as a generic or equivalent version of a branded medication. FDA announced warning letters to 30 telehealth companies on March 3, 2026, identifying sameness claims and obscured sourcing as principal concerns.

Where does state law change the answer?

Federal advertising rules apply nationally, but ownership, medical-director authority, telehealth licensure, supervision, prescribing, and entity structure vary by state. The advertiser should review the state where the patient is located, not assume that a compliant national template works everywhere.

California

The Medical Board of California states that a medical spa providing medical procedures is practicing medicine and that medical spas offering medical procedures must be physician-owned. The Board also states that a lay-owned business generally cannot provide medical evaluation, diagnosis, care, or treatment merely by contracting with a physician as a medical director. Physicians treating patients located in California must be California-licensed, and telehealth is held to the same standard of care as in-person practice.

California also addresses fictitious-name permits for professional medical corporations operating only through telehealth. A telehealth landing page may therefore raise entity, ownership, and display questions in addition to claim questions.

Texas

The Texas Medical Board states that nonphysician entities and individuals may not practice medicine and that physicians must retain independent medical judgment. Texas board materials and an April 2024 bulletin also provide an enforcement signal concerning a practice that advertised and offered cosmetic and weight-loss injections without appropriate physician or midlevel involvement.

A Texas med spa should avoid copy implying that a nonphysician business independently diagnoses, prescribes, or administers treatment. A nominal medical director arrangement does not by itself answer whether the operating model is lawful.

New York

New York Department of Health materials state that ordinary business corporations and limited liability companies generally may not provide medical services unless they qualify as an authorized facility structure. New York telehealth guidance also emphasizes practitioner credentialing, records access, and professional responsibilities.

The identity of the medical practice, the entity contracting with the patient, and the entity controlling clinical decisions should be reviewed alongside the campaign.

Florida

Florida materials reviewed for this topic address ownership and registration requirements for pain-management clinics, including physician relationships involving controlled-substance prescribing. They do not establish a universal ownership rule for every weight-loss med spa. Florida owners should not automatically apply pain-management clinic rules to a weight-management program; the services, medications, facility classification, and prescriber relationships must be evaluated under applicable Florida requirements.

These examples show why state law decides important operational questions. They are not a national rule, and rules vary by state. A state medical board, qualified healthcare counsel, or other appropriate reviewer should assess the entity, clinician, telehealth, and advertising structure before launch.

What should the med spa compliance workflow look like?

Use this sequence before a campaign goes live:

1. 1Identify the parties. Name the legal medical practice, clinician, advertiser, and dispensing pharmacy or compounder accurately.
2. 2Inventory every claim. Mark service, medication, outcome, safety, comparison, testimonial, FDA-status, and pharmacy claims.
3. 3Match evidence. Confirm that the evidence applies to the actual product, program, population, and conditions described.
4. 4Remove guarantees. Delete rapid, effortless, permanent, universal, or no-lifestyle-change promises.
5. 5Audit visuals. Review photos, charts, badges, logos, product images, and clinician imagery for implied claims.
6. 6Separate product categories. Keep FDA-approved medication claims distinct from compounded-medication language.
7. 7Review disclosures in context. Place material disclosures near the claim in clear, conspicuous language.
8. 8Check state structure. Verify ownership, licensure, supervision, telehealth, prescribing, and advertising requirements in every target state.
9. 9Control vendors. Require preapproval, compliance obligations, records, and rapid removal rights in marketing agreements.
10. 10Preserve the file. Save final ads, drafts, approvals, studies, labels, pharmacy information, and publication dates.

Owners adding a program should also map responsibilities before selecting technology. The GLP-1 telehealth program launch timeline covers the broader operational work beyond advertising, while the build-versus-white-label GLP-1 comparison helps frame the infrastructure decision.

Build a defensible campaign

The strongest med spa campaign is not the one with the most aggressive promise. It is the one that accurately identifies the service, keeps clinical decisions with licensed clinicians, distinguishes approved and compounded products, preserves substantiation, and adapts the operating model to each state.

For owners extending an existing spa, a white-label telehealth platform can organize the business workflow without turning advertising language into a clinical guarantee. Review the campaign, entity structure, clinician arrangement, pharmacy description, and state requirements as one system before publication. Owners weighing infrastructure can see the GLP-1 weight management program and compare its operational fit.

Related reading: the full guide this article belongs to.